期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 33, 期 4, 页码 307-320出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2008.10.010
关键词
AIDS; HIV; Nucleoside reverse transcriptase inhibitors (NRTIs); Nucleotide reverse transcriptase inhibitors (NtRTIs); Non-nucleoside reverse transcriptase inhibitors (NNRTIs); Protease inhibitors; Fusion inhibitors; Co-receptor inhibitors; Integrase inhibitors
In 2008, 25 years after the human immunode efficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical use in the treatment of AIDS. These compounds fall into six categories: nucleoside reverse transcriptase inhibitors (NRTIs: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine); nucleotide reverse transcriptase inhibitors (NtRTIs: tenofovir); non-nucleoside reverse transcriptase inhibitors (NNRTIs: nevirapine, delavirdine, efavirenz and etravirine); protease inhibitors (PIs: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir); cell entry inhibitors [fusion inhibitors (FIs: enfuvirtide) and co-receptor inhibitors (CRIs: maraviroc)]; and integrase inhibitors (INIs: raltegravir). These compounds should be used in drug combination regimens to achieve the highest possible benefit, tolerability and compliance and to diminish the risk of resistance development. (c) 2008 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据